Research Article
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
Table 1
Patient and health control characteristics.
| | Healthy | Patients | value (where applicable) |
| | Number of enrolments | 54 | 86 (59 NAFLD, 27 HCV SVR) | | | Average age (range) | 28 (19-61) | 59 (31-75) | <0.0001 | | Average BMI (range) | 23.9 (17-31.7) | 30.9 (18.8–41.6) | <0.0001 | | Gender | 16/54 (30%) male | 54/85 (63%) male | <0.0001 | | Median AST | NA | 28 (6–367) | NA | | Median ALT | NA | 30 (9–217) | NA | | Median platelets | NA | 201.5 (63-536) | NA | | Median FIB-4 | NA | 1.475 (0.33–7.165) | NA |
|
|
